On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Company’s COVID-19 variant-specific vaccine candidates showed that the Company’s variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increased neutralizing titers against SARS-CoV-2 variants of concern.

To date, the Company had delivered approximately 132 million doses of the Moderna COVID-19 Vaccine globally.